Genmab Announces 2019 Net Sales Figures for DARZALEX® (daratumumab) and Achievement of USD 150 Million Sales Milestone in DARZALEX Collaboration with Janssen
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: GlobeNewswire
Company Announcement Net trade sales of DARZALEX in 2019 totaled USD 2,998 millionGenmab to receive milestone payment of USD 150 million in DARZALEX collaborationMilestone triggered by sales of DARZALEX reaching USD 3 billion in the calendar year of 2019 as calculated on the basis of the license agreement terms Copenhagen, Denmark; January 22, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab) as reported by Johnson & Johnson were USD 2,998 million in 2019. Net trade sales were USD 1,567 million in the U.S. and net trade sales in the rest of the world were USD 1,430 million. Genmab receives royalties on the worldwide net sales of DARZALEX as calculated on the basis of the license agreement terms under the exclusive worldwide license to Janssen Biotech, Inc. (Janssen) to develop, manufacture and commercialize DARZALEX. Worldwide net trade sales of DARZALEX in 2018 were USD 2,025 million, resulting in royalty income of DKK 1,708
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.MarketBeat
- Genmab A/S 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]Seeking Alpha
- Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at BNP Paribas from a "strong sell" rating to a "hold" rating.MarketBeat
- Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $27.00 price target on the stock.MarketBeat
- Genmab Publishes 2024 Annual Report [Yahoo! Finance]Yahoo! Finance